Adult Dosing

Tinea corporis, tinea cruris (cream and lotion)

• Apply to affected areas qd-bid for 2 wks

Tinea pedis (cream and lotion)

• Apply to affected areas qd-bid for 1 month

Tinea (pityriasis) versicolor (cream)

• Apply to affected areas qd for 2 wks

• Re-evaluate the patient if there is no significant improvement after the treatment period

Pediatric Dosing

Tinea corporis, tinea cruris (cream)

• Apply to affected areas qd-bid for 2 wks

Tinea pedis (cream)

• Apply to affected areas qd-bid for 1 month

Tinea (pityriasis) versicolor (cream)

• Apply to affected areas qd for 2 wks

• Re-evaluate the patient if there is no significant improvement after the treatment period
• These indications for which the oxiconazole cream is effective rarely occur in children <12 yrs of age

• Topical treatment of dermal infections including tinea pedis, tinea cruris, and tinea corporis (both cream and lotion)
• Treatment of tinea (pityriasis) versicolor (cream only)

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Not recommended for ophthalmic or intravaginal use
• If there is a reaction suggestive of sensitivity and chemical or epidermal irritation, discontinue treatment and institute appropriate therapy
• Avoid use of occlusive dressings unless otherwise indicated

Supplemental Patient Information

• Advice patients to avoid contact with eyes, nose, mouth, and other mucous membranes
• Instruct patients to promptly inform their physicians on occurrence of increased irritation, itching, burning, blistering, swelling, or oozing
• Advise patients to contact their physicians if no improvement is seen after 2-4 wks or sooner if the condition worsens

Pregnancy Category:B

Breastfeeding: Topically applied oxiconazole is minimally absorbed and thus considered a low risk to the breastfed infant. Avoid application to the nipple area and ensure that the infant’s skin does not come into direct contact with the treated areas. Wipe off excess cream before breastfeeding. This data is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/ht mlgen?LACT last accessed 7 June 2011). Manufacturer advises caution.

• DERM: Pruritus, burning

• Antifungal; inhibits biosynthesis of ergosterol, which is critical for cytoplasmic membrane integrity of fungi
• Minimal systemic absorption
• Metabolism: Unknown
• Excretion: Urine (<0.3%)
• Half-life: Unknown

US Trade Name(s)

• Oxistat

US Availability

Oxistat

• CRE: 1%
• LOTN: 1%

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Dermatologic

Antifungals (Topical)

Azole Derivatives

Pricing data from www.DrugStore.com in U.S.A.

• Oxistat 1 % LOTN [Bottle] (PHARMADERM)
  30 % = $116.13
  90 % = $343.08
• Oxistat 1 % CREA [Tube] (PHARMADERM)
  60 % = $202.98
  180 % = $599.99
• Oxistat 1 % CREA [Tube] (PHARMADERM)
  30 % = $108.63
  90 % = $316.29

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.